Feline Hypertension (Systemic Arterial Hypertension)

Feline systemic arterial hypertension (SAH) is defined as a sustained elevation in systemic blood pressure that causes, or has the potential to cause, target organ damage (TOD) [1]. It is one of the most commonly diagnosed cardiovascular conditions in older cats, frequently occurring secondary to underlying diseases such as chronic kidney disease (CKD) and hyperthyroidism, though a primary (idiopathic) form also exists [8]. The condition is particularly insidious because cats may show no obvious clinical signs until severe, potentially irreversible damage has occurred to the eyes, kidneys, brain, or heart [8]. Early identification and prompt management are therefore critical to preserving quality of life and preventing life-threatening complications [1].

Classification

Feline hypertension is classified into three categories [1]:

• ·Secondary hypertension: BP elevation caused by an identifiable underlying disease (the most common form in cats)
• ·Primary (idiopathic) hypertension: No underlying cause identified despite thorough investigation
• ·White-coat hypertension: Transient BP elevation due to the stress of the clinical environment, which must be distinguished from true hypertension [1]

Underlying Causes of Secondary Hypertension

Chronic Kidney Disease (CKD): The most frequently associated comorbidity. CKD leads to sodium and water retention, activation of the renin-angiotensin-aldosterone system (RAAS), and reduced renal clearance — all of which drive blood pressure elevation. Hypertension, in turn, accelerates glomerular injury, creating a destructive feedback cycle [3][5].

Hyperthyroidism: Excess thyroid hormone increases cardiac output, heart rate, and blood volume, and reduces systemic vascular resistance acutely; however, the net effect on renal perfusion and RAAS activation results in sustained hypertension in many affected cats. Notably, treating hyperthyroidism can unmask pre-existing CKD and paradoxically worsen hypertension in some cats [8].

Primary Hyperaldosteronism (Conn's Syndrome): An increasingly recognized but likely underdiagnosed adrenocortical disease in cats [4]. Autonomous aldosterone secretion (from an adrenal adenoma, carcinoma, or bilateral hyperplasia) causes sodium retention, potassium wasting, and volume expansion, leading to hypertension and hypokalemia. It is now considered the most common adrenocortical disease in cats [4].

Diabetes Mellitus: Associated with hypertension through mechanisms similar to those in humans, including RAAS activation and endothelial dysfunction.

Acromegaly and Hyperadrenocorticism: Less common endocrine causes that may contribute to elevated BP.

Pathophysiological Mechanisms

The RAAS plays a central role in blood pressure regulation and its dysregulation [5]. Angiotensin II causes direct vasoconstriction, stimulates aldosterone release (promoting sodium and water retention), and has pro-fibrotic and pro-inflammatory effects on the cardiovascular and renal systems [5]. Chronic RAAS activation — as occurs in CKD, hyperaldosteronism, and heart disease — leads to progressive remodeling of vascular, cardiac, and renal tissue [5].

Target organ damage (TOD) occurs when sustained high blood pressure (generally >160 mmHg systolic, and especially >180 mmHg) damages the microvasculature and end organs [1]:

• ·Ocular TOD: Hypertensive retinopathy, choroidopathy, retinal hemorrhage, and retinal detachment
• ·Renal TOD: Glomerulosclerosis, proteinuria, and progressive nephron loss
• ·Cardiovascular TOD: Left ventricular hypertrophy (LVH), concentric cardiac remodeling, and increased risk of congestive heart failure [2]
• ·Neurological TOD: Hypertensive encephalopathy, cerebrovascular accidents, intracranial hemorrhage

The ACVIM consensus classifies blood pressure risk as follows [1]:

Blood Pressure Measurement

The cornerstone of diagnosis is accurate, reproducible blood pressure measurement [1]. The recommended methods in cats are:

• ·Doppler sphygmomanometry: Considered the gold standard for cats; provides reliable systolic BP readings. The cuff is typically placed on the forelimb (metacarpal region) or tail base, and the cuff width should be approximately 30–40% of the limb circumference [1][8].
• ·High-Definition Oscillometry (HDO): An acceptable alternative; provides systolic, diastolic, and mean arterial pressures [1].
• ·Measurement protocol: A minimum of 5–7 consistent readings should be obtained after a 5–10 minute acclimatization period in a quiet room, ideally with the owner present. The first reading is typically discarded [1][8]. White-coat effect must be accounted for, and diagnosis should not be made on a single visit unless TOD is already evident [1].

Physical Examination Findings

• ·Fundic examination: Retinal hemorrhage, detachment, tortuous vessels, or papilledema
• ·Cardiovascular auscultation: Murmur, gallop rhythm, or arrhythmia [2]
• ·Neurological assessment: Mentation, gait, and cranial nerve evaluation

Laboratory Diagnostics

A comprehensive workup is essential to identify underlying causes [1][8]:

• ·

  Complete Blood Count (CBC):

  • ·HCT (Hematocrit): May be decreased (anemia of CKD) [3] or elevated (polycythemia, a rare cause of hypertension)
  • ·WBC: May be elevated if concurrent infectious or inflammatory disease is present
  • ·PLT: Generally unremarkable, but thrombocytopenia may complicate hemorrhagic TOD
• ·

  Serum Biochemistry Panel:

  • ·CREA (Creatinine) and BUN (Blood Urea Nitrogen): Elevated in CKD, the most common underlying cause [3]; CREA is used for IRIS CKD staging
  • ·Phosphorus: Elevated in advanced CKD [3]
  • ·Potassium (K⁺): Low (hypokalemia) is a hallmark of primary hyperaldosteronism [4]; severe hypokalemia (<3.0 mEq/L) may cause muscle weakness
  • ·ALT (Alanine Aminotransferase): May be elevated in hyperthyroidism or hepatic congestion
  • ·TBIL (Total Bilirubin): Generally unremarkable unless hepatic involvement
  • ·ALB (Albumin): May be low if significant proteinuria or concurrent protein-losing nephropathy is present
  • ·GLOB (Globulins): Variable; may be elevated with chronic inflammation
  • ·Sodium (Na⁺): May be elevated or at high-normal in hyperaldosteronism due to sodium retention [4]
  • ·Glucose: Assessed to exclude diabetic hypertension
• ·

  Urinalysis:

  • ·Urine Protein-to-Creatinine Ratio (UPC): Elevated UPC (>0.2 in cats) indicates proteinuria, a marker of glomerular hypertensive damage and an important prognostic indicator [1][3]
  • ·Urine specific gravity (USG): Low in CKD (isosthenuria, USG 1.007–1.015)
  • ·Urine sediment: May reveal casts in nephropathy
• ·

  Thyroid Function:

  • ·Total T4 (Thyroxine): Elevated in hyperthyroidism; should be measured in all hypertensive cats, especially those >7 years [7][8]
  • ·Free T4 by equilibrium dialysis if total T4 is equivocal
• ·

  Aldosterone and Renin:

  • ·Plasma aldosterone concentration (PAC) elevated and plasma renin activity (PRA) suppressed in primary hyperaldosteronism [4]
  • ·Aldosterone-to-renin ratio (ARR) is the primary screening test for Conn's syndrome [4]
• ·

  Adrenal Imaging:

  • ·Abdominal ultrasound: Adrenal mass or bilateral hyperplasia in hyperaldosteronism [4]; renal architecture in CKD [3]
  • ·CT scan for more detailed adrenal characterization
• ·

  Echocardiography:

  • ·Concentric left ventricular hypertrophy (LVH) and increased interventricular septum thickness suggest hypertensive cardiomyopathy [2]
  • ·Important to differentiate pressure-overload LVH from primary HCM [2]
• ·

  Ophthalmologic Examination:

  • ·Fundoscopy to grade retinopathy and identify acute TOD [8]

General Principles

Treatment is indicated in cats with [1]:

• ·Systolic BP ≥180 mmHg (high risk of TOD) — treat promptly
• ·Systolic BP 160–179 mmHg with evidence of TOD — treat
• ·Systolic BP 160–179 mmHg without TOD — consider treating after repeat confirmation
• ·Cats with white-coat hypertension and no TOD — monitor without medication

The target blood pressure is generally <160 mmHg systolic, with a preference for ≤150 mmHg in cats with proteinuria or established TOD [1][8].

Antihypertensive Pharmacotherapy

1. Amlodipine Besylate (First-Line Agent) Amlodipine, a long-acting dihydropyridine calcium channel blocker, is the drug of choice for managing feline hypertension [1][8]. It causes potent arterial vasodilation and is highly effective in reducing BP in cats.

• ·Starting dose: 0.625–1.25 mg/cat PO q24h (approximately 0.1–0.25 mg/kg)
• ·Higher doses (up to 2.5 mg/cat) may be required in refractory cases
• ·Re-evaluation of BP should occur 7–14 days after initiation or dose change [1][8]
• ·Highly effective as monotherapy in most cats

2. RAAS Inhibitors

• ·ACE Inhibitors (ACEi): Benazepril or enalapril (0.5–1 mg/kg PO q24h) are commonly used as adjunctive therapy, particularly in cats with concurrent CKD and proteinuria, to reduce glomerular hypertension and slow CKD progression [5][8]. They are less effective as monotherapy for BP reduction in cats compared to amlodipine.
• ·Angiotensin Receptor Blockers (ARBs): Telmisartan has demonstrated efficacy for BP reduction and antiproteinuric effects in cats. It is gaining favor as an alternative or adjunct to ACEi [1][8].

3. Spironolactone / Fludrocortisone:

• ·Used in cases of primary hyperaldosteronism as a mineralocorticoid receptor antagonist [4]
• ·Spironolactone (2 mg/kg PO q24h) helps manage hypokalemia and hypertension associated with Conn's syndrome [4]

4. Potassium Supplementation:

• ·Essential in cats with hyperaldosteronism-associated hypokalemia [4]
• ·Oral potassium gluconate supplementation titrated to normalize serum potassium

Management of Underlying Disease

• ·CKD: Dietary modification (reduced phosphorus, controlled sodium, omega-3 fatty acid supplementation), phosphorus binders, and anti-hypertensive therapy to slow progression [3][5]
• ·Hyperthyroidism: Radioactive iodine (¹³¹I), methimazole, surgical thyroidectomy, or prescription iodine-restricted diet. Successful treatment often significantly reduces BP, but may unmask CKD [8]
• ·Primary Hyperaldosteronism: Surgical adrenalectomy is curative for unilateral adrenal adenoma/carcinoma; medical management with spironolactone and potassium supplementation for non-surgical candidates [4]

Emergency / Hypertensive Crisis Management

• ·Acute, severe hypertension with active retinal detachment or neurological signs requires urgent intervention
• ·Amlodipine at higher doses or additional agents (e.g., hydralazine) may be used in the short term
• ·Avoid overly rapid BP reduction, which can precipitate ischemic organ damage [1]

Monitoring

• ·BP re-check 5–7 days after initiating or changing therapy, then every 1–3 months once stable [1][8]
• ·Routine biochemistry (CREA, BUN, electrolytes, UPC) every 3–6 months [1]
• ·Fundic examination at each visit until stable [8]

General Prognosis

The prognosis for hypertensive cats is highly variable and depends on [1][8]:

1. ·The severity and duration of hypertension at diagnosis
2. ·The extent of target organ damage already present
3. ·Whether an underlying, treatable cause can be identified and managed
4. ·Owner compliance with long-term monitoring and medication

Ocular Outcomes

Acute retinal detachment is one of the most devastating complications of feline hypertension. Visual prognosis is guarded to poor once complete retinal detachment has occurred; however, partial or complete vision restoration is possible in some cats if antihypertensive treatment is initiated within 24–72 hours of detachment [8]. After 72 hours, the likelihood of vision recovery decreases substantially, and chronic detachment is generally associated with permanent blindness [8].

Renal Outcomes

Hypertension accelerates the progression of CKD through glomerulosclerosis and proteinuria [3][5]. Effective BP control reduces proteinuria and may significantly slow CKD progression, thereby extending survival. However, if severe hypertensive nephropathy has already occurred, renal prognosis is guarded [3].

Cardiac Outcomes

Left ventricular hypertrophy secondary to hypertension carries risks of diastolic dysfunction, congestive heart failure, and arrhythmias [2]. Cats with concurrent HCM or advanced cardiac remodeling have a more guarded prognosis [2].

Hyperaldosteronism Outcomes

Cats with primary hyperaldosteronism that undergo successful surgical adrenalectomy for benign adenoma may have an excellent long-term prognosis [4]. Those with malignant adrenocortical carcinoma have a more guarded outlook, with survival dependent on completeness of resection and absence of metastasis [4]. Medically managed cats can achieve good quality of life but require lifelong therapy [4].

Survival Statistics

Specific population-level survival statistics for feline hypertension as an isolated condition are not robustly defined in the referenced literature; outcomes are strongly confounded by the nature and severity of comorbidities (CKD, hyperthyroidism, hyperaldosteronism). The ISFM guidelines emphasize that early diagnosis and treatment significantly improve outcomes and reduce the risk of severe, irreversible TOD [8]. Cats whose underlying disease is effectively managed and whose BP is well-controlled can live comfortably for months to years following diagnosis [1][8]. Uncontrolled, severe hypertension (>180 mmHg with TOD) carries a poor short-term prognosis without intervention [1].

Routine Blood Pressure Monitoring

Because feline hypertension is frequently asymptomatic until severe TOD has occurred, routine screening is the most effective preventive strategy [1][7][8]:

• ·The AAFP Senior Care Guidelines recommend blood pressure measurement at every wellness visit for cats aged 7 years and older [7]
• ·The ISFM and ACVIM recommend screening all cats with diseases known to be associated with hypertension (CKD, hyperthyroidism, hyperaldosteronism, diabetes) regardless of age [1][8]
• ·Cats with previously identified prehypertension (140–159 mmHg) should be rechecked every 3–6 months [1]

Management of Predisposing Diseases

• ·CKD: Early diagnosis via routine senior wellness bloodwork (CREA, BUN, phosphorus, urinalysis with USG and UPC), prompt IRIS staging, and implementation of renal-protective diets and therapies [3][7]
• ·Hyperthyroidism: Annual or semi-annual total T4 screening in cats >7 years of age allows early detection and treatment before hypertension develops [7][8]
• ·Primary Hyperaldosteronism: Clinicians should maintain a high index of suspicion in hypertensive cats with hypokalemia, and pursue appropriate diagnostic workup (aldosterone, renin, adrenal imaging) rather than treating BP alone [4]

Dietary and Lifestyle Measures

• ·Controlled dietary sodium intake may be appropriate in cats with established hypertension or at-risk conditions, though the evidence base for sodium restriction as a sole intervention is limited [3][8]
• ·Maintenance of healthy body weight, as obesity may contribute to RAAS activation and cardiovascular risk
• ·Stress reduction in the hospital environment is important to distinguish true hypertension from white-coat effect and to ensure accurate monitoring [1]

There Is No Vaccine

Feline systemic hypertension is a non-infectious, multifactorial disease. No vaccine exists or is applicable. Prevention relies entirely on proactive screening, early detection of predisposing conditions, and timely medical management [1][8].